TABLE IV.
Summary of survivor’s immune reconstitution 1 year and at last follow-up following unconditioned HCT
| Matched Sibling Donor | Unrelated Donor: Adult or Umbilical Cord Blood | |||||||
|---|---|---|---|---|---|---|---|---|
| IL2RG/JAK3 | ADA | Other° | Overall | IL2RG/JAK3 | ADA | Other° | Overall | |
| # Evaluable; 1-year from HCT (+/− 1 mo) | 19 | 21 | 19 | 59 | 16 | 5 | 3 | 24 |
| CD3 (× 106/L) | 3428 (1751–9287) | 1008 (364–2500) | 744 (27–5698) | 1764 (27–9287) | 2153 (66–4673)* | 572 (540–2144) | 1414 (421–3233) | 1767 (66–4673) |
| CD4 (× 106/L) | 1766 (921–2653) | 405 (132–1330) | 330 (17–3773) | 585 (17–3773) | 1241 (21–3027) | 293 (272–530) | 853 (308–2221) | 692 (21–3027) |
| CD4/CD45RA (%) | 33 (17–78) | 14 (3–22) | 8 (1–82) | 21 (1–78) | 57 (9–94) | 55 (8–80) | 26 (19–32) | 55 (8–94) |
| CD8 (× 106/L) | 1180 (444–6302) | 370 (194–1114) | 298 (8–6646) | 764 (8–6646) | 770 (45–2350) | 207 (192–1503) | 541 (189–857) | 550 (45–2350) |
| B Cells (× 106/L) | 1200 (30–2571) | 50 (9–333) | 5 (0–1155) | NA | 280 (0–3602) | 25 (22–30) | 150 (11–333) | NA |
| NK Cells (× 106/L) | 142 (47–392) | 40 (0–602) | 260 (125–804) | NA | 52 (0–297) | 43 (10–78) | 251 (184–291) | NA |
| PHA (%) | 79 (8–100) | 76 (58–100) | 48 (16–100) | 59 (8–100) | 100 (69–100) | 86 (72–100) | 85 (85) | 100 (69–100) |
| Off gammaglobulin | 13 (68%) | 16 (76%) | 8 (47%) | 37 (63%) | 1 (6%) | 1 (20%) | 0 (0%) | 2 (8%)* |
| # Evaluable; At last follow-up | 20 | 20 | 17 | 57 | 16 | 5 | 2 | 23 |
| Time to last fu (years) | 5.5 (1–14.4) | 6.3 (2–17.1) | 7.5 (1.6–18.9) | 6.9 (1–18.9) | 4.3 (1–19) | 2.5 (1.1–12.3) | 2.8 (1.6–3.9) | 3.9 (1–19) |
| CD3 (× 106/L) | 2230 (1190–9287) | 1720 (578–4440) | 1000 (230–2606) | 1814 (230–9287) | 1864 (315–4210) | 1328 (593–6017) | 6091 (383–10790)* | 1574 (315–10790) |
| CD4 (× 106/L) | 1302 (458–2653) | 1065 (298–3330) | 432 (140–1640) | 944 (140–3330) | 943 (144–2330) | 506 (272–1105) | 3623 (247–6999)* | 840 (144–6999) |
| CD4/CD45RA (%) | 60 (17–80) | 13 (2–17) | 11 (3–71) | 19 (2–80) | 43 (4–94) | 8 (4–41) | 26 (0–51) | 35 (0–94) |
| CD8 (× 106/L) | 982 (468–6302) | 757 (220–2040) | 313 (140–1026) | 772 (220–2040) | 575 (80–1853) | 613 (199–4851) | 2007 (570–3443) | 580 (80–4851) |
| B Cells (× 106/L) | 460 (347–1879) | 180 (36–750) | 24 (0–395) | NA | 399 (0–3602) | 47 (30–137) | 1017 (338–1696) | NA |
| NK Cells (× 106/L) | 85 (0–392) | 131 (0–1025) | 115 (37–524) | NA | 29 (0–194) | 98 (10–363) | 306 (274–338) | NA |
| PHA (%) | 100 (66–100) | 100 (46–100) | 86 (47–100) | 100 (46–100) | 100 (65–100) | 72 (72) | 85 (85) | 100 (65–100) |
| Off gammaglobulin | 16 (80%) | 18 (90%) | 10 (59%) | 44 (77%) | 4 (25%) | 2 (40%) | 1 (50%) | 7 (30%)* |
| Donor Myeloid >5% | 7/16 (44%) | 8/15 (53%) | 7/15 (47%) | 22/46 (48%) | 6/13 (46%) | 2/4 (50%) | 1/1 (100%) | 9/18 (50%) |
*
P <0.05 compared to sibling donor recipients
°See methods for details